<DOC>
	<DOCNO>NCT02233712</DOCNO>
	<brief_summary>An open label , dose-finding , schedule-changing , sequential , multiple dose , multi-center study patient Stage I-III gastric cancer . The first group patient receive start dose 250 µg week 0 , 1 , 3 . Thereafter , allocation treatment 100 µg 500 µg base antibody response dose tolerability .</brief_summary>
	<brief_title>Open-label , Dose-finding Study Determine Antibody Response G17DT Treatment Patients With Gastric Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Histologically confirm UICC Stage I , II III gastric adenocarcinoma . Must macroscopically curative resection gastric cancer absence metastatic disease time entry trial Male female 18 year age Must life expectancy least three month World Health Organization Performance Status 0 1 Given write conform consent Gastric surgery within four week baseline ( week 0 ) gastric surgery anticipate period study History malignant disease within previous five year , except nonmelanomatous skin cancer situ carcinoma uterine cervix Previous use within last four week , concomitant use anticipate use period study , anticancer therapy Concomitant use immunosuppressant , include systemic ( i.e . oral inject ) corticosteroid Females pregnant , plan become pregnant lactate Taking part another study involve investigational license drug device three month precede enrollment study Previously receive G17DT treatment Haemoglobin ( Hb ) &lt; 10.0 g/dL White blood cell count ( WBC ) &lt; 4.0 x 10^9/L Platelets &lt; 100 x 10^9/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>gastric cancer , stomach neoplasm ,</keyword>
</DOC>